Overview Dividends

(ACLS) Axcelis Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0545402085

Ion Implanters, Spare Parts, Upgrades, Maintenance, Training

ACLS EPS (Earnings per Share)

EPS Growth (3Y CAGR): -11.82%
EPS Trend (3Y Correlation): -70.7%

ACLS Revenue

Revenue Growth (3Y CAGR): -7.67%
Revenue Trend (3Y Correlation): -73.1%

Risk via 10d forecast
Volatility	48.1%
Value at Risk 5%th	74.3%
Relative Tail Risk	-6.22%

Reward TTM
Sharpe Ratio	0.22
Alpha	-20.94

Character TTM
Hurst Exponent	0.593
Beta	1.571
Beta Downside	1.588

Drawdowns 3y
Max DD	78.84%
Mean DD	38.66%
Median DD	43.76%

Description: ACLS Axcelis Technologies November 10, 2025

Axcelis Technologies (NASDAQ: ACLS) designs, manufactures, and services ion-implantation and related semiconductor processing equipment for chip makers across the U.S., Europe, and Asia-Pacific. Its product line spans high-energy/high-current implanters for advanced nodes, medium-current tools for legacy processes, and a suite of aftermarket services such as used-tool refurbishment, spare-part logistics, upgrades, and customer training, all sold through a direct sales organization.

Key performance indicators that investors watch include: (1) Revenue growth – the company reported FY 2024 revenue of $1.02 billion, a 7 % YoY increase driven by higher equipment orders and service contracts; (2) Order backlog – a roughly $1.3 billion backlog representing ~12 months of forward-filled demand, indicating a relatively tight supply-demand balance; and (3) Gross margin – stable around 38 % despite inflationary pressure on components, reflecting pricing power in a niche, high-mix market.

Sector-level drivers shaping Axcelis’ outlook are the global semiconductor capital-expenditure cycle (with 2024-25 fab-spending projected to rise 9 % YoY by SEMI), the shift toward advanced-node technologies that increase demand for high-energy implanters, and geopolitical incentives (e.g., U.S. CHIPS Act funding) that are accelerating domestic fab expansion, thereby boosting domestic equipment spend.

For a deeper, data-rich analysis of ACLS’s valuation dynamics and comparable peers, you may find ValueRay’s research platform a useful next step.

ACLS Stock Overview

Market Cap in USD	2,561m
Sub-Industry	Semiconductor Materials & Equipment
IPO / Inception	2000-07-11
Return 12m vs S&P 500	-9.78%
Analyst Rating	3.57 of 5

ACLS Dividends

Currently no dividends paid

ACLS Growth Ratios

CAGR 3y	2.13%
CAGR/Max DD Calmar Ratio	0.03
CAGR/Mean DD Pain Ratio	0.06
Current Volume	481.7k
Average Volume	573.2k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (135.9m TTM) > 0 and > 6% of Revenue (6% = 51.2m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA -3.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 92.02% (prev 80.86%; Δ 11.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 137.7m > Net Income 135.9m (YES >=105%, WARN >=100%)

Net Debt (-114.8m) to EBITDA (178.5m) ratio: -0.64 <= 3.0 (WARN <= 3.5)

Current Ratio 4.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (31.4m) change vs 12m ago -3.75% (target <= -2.0% for YES)

Gross Margin 44.68% (prev 44.28%; Δ 0.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 63.43% (prev 80.39%; Δ -16.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 14.75 (EBITDA TTM 178.5m / Interest Expense TTM 10.9m) >= 6 (WARN >= 3)

Altman Z'' 7.33

(A) 0.58 = (Total Current Assets 984.0m - Total Current Liabilities 199.0m) / Total Assets 1.35b

(B) 0.36 = Retained Earnings (Balance) 488.8m / Total Assets 1.35b

(D) 1.47 = Book Value of Equity 487.2m / Total Liabilities 331.8m

Total Rating: 7.33 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.45

1. Piotroski 5.50pt = 0.50

2. FCF Yield 5.68% = 2.84

3. FCF Margin 14.54% = 3.63

4. Debt/Equity 0.07 = 2.50

5. Debt/Ebitda -0.64 = 2.50

6. ROIC - WACC (= 1.90)% = 2.38

7. RoE 13.31% = 1.11

8. Rev. Trend -73.06% = -5.48

9. EPS Trend -70.68% = -3.53

What is the price of ACLS shares?

As of November 15, 2025, the stock is trading at USD 81.54 with a total of 481,691 shares traded.
Over the past week, the price has changed by -4.90%, over one month by +1.44%, over three months by -2.64% and over the past year by +3.41%.

Is Axcelis Technologies a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Axcelis Technologies is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 56.45 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACLS is around 71.99 USD . This means that ACLS is currently overvalued and has a potential downside of -11.71%.

Is ACLS a buy, sell or hold?

Axcelis Technologies has received a consensus analysts rating of 3.57. Therefor, it is recommend to hold ACLS.

Strong Buy: 2
Buy: 0
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ACLS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	96.8	18.7%
Analysts Target Price	96.8	18.7%
ValueRay Target Price	82.6	1.3%

ACLS Fundamental Data Overview November 15, 2025

Market Cap USD = 2.56b (2.56b USD * 1.0 USD.USD)
P/E Trailing = 19.4859
P/E Forward = 19.9203
P/S = 3.002
P/B = 2.5966
P/EG = 1.23
Beta = 1.726
Revenue TTM = 853.1m USD
EBIT TTM = 161.0m USD
EBITDA TTM = 178.5m USD
Long Term Debt = 42.3m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 6.27m USD (from shortTermDebt, last quarter)
Debt = 72.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -114.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.18b USD (2.56b + Debt 72.7m - CCE 449.6m)
Interest Coverage Ratio = 14.75 (Ebit TTM 161.0m / Interest Expense TTM 10.9m)
FCF Yield = 5.68% (FCF TTM 124.0m / Enterprise Value 2.18b)
FCF Margin = 14.54% (FCF TTM 124.0m / Revenue TTM 853.1m)
Net Margin = 15.93% (Net Income TTM 135.9m / Revenue TTM 853.1m)
Gross Margin = 44.68% ((Revenue TTM 853.1m - Cost of Revenue TTM 472.0m) / Revenue TTM)
Gross Margin QoQ = 41.57% (prev 44.90%)
Tobins Q-Ratio = 1.62 (Enterprise Value 2.18b / Total Assets 1.35b)
Interest Expense / Debt = 9.29% (Interest Expense 6.75m / Debt 72.7m)
Taxrate = 13.81% (4.16m / 30.1m)
NOPAT = 138.8m (EBIT 161.0m * (1 - 13.81%))
Current Ratio = 4.95 (Total Current Assets 984.0m / Total Current Liabilities 199.0m)
Debt / Equity = 0.07 (Debt 72.7m / totalStockholderEquity, last quarter 1.02b)
Debt / EBITDA = -0.64 (Net Debt -114.8m / EBITDA 178.5m)
Debt / FCF = -0.93 (Net Debt -114.8m / FCF TTM 124.0m)
Total Stockholder Equity = 1.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.05% (Net Income 135.9m / Total Assets 1.35b)
RoE = 13.31% (Net Income TTM 135.9m / Total Stockholder Equity 1.02b)
RoCE = 15.15% (EBIT 161.0m / Capital Employed (Equity 1.02b + L.T.Debt 42.3m))
RoIC = 13.60% (NOPAT 138.8m / Invested Capital 1.02b)
WACC = 11.70% (E(2.56b)/V(2.63b) * Re(11.80%) + D(72.7m)/V(2.63b) * Rd(9.29%) * (1-Tc(0.14)))
Discount Rate = 11.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.42%
[DCF Debug] Terminal Value 63.34% ; FCFE base≈144.8m ; Y1≈129.1m ; Y5≈108.9m
Fair Price DCF = 37.17 (DCF Value 1.15b / Shares Outstanding 31.0m; 5y FCF grow -13.36% → 3.0% )
EPS Correlation: -70.68 | EPS CAGR: -11.82% | SUE: 1.12 | # QB: 4
Revenue Correlation: -73.06 | Revenue CAGR: -7.67% | SUE: 3.87 | # QB: 4

Additional Sources for ACLS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle